Tango Therapeutics (TNGX) Enterprise Value (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Enterprise Value of -$157.8 million for Q1 2026, up 27.18% year-over-year from -$124.1 million in Q1 2025, and down 40.03% quarter-over-quarter from -$112.7 million in Q4 2025.
Tango Therapeutics (TNGX) Enterprise Value (2020 - 2026) Analysis & Trends
Tango Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$157.8 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 27.18% year-over-year to -$157.8 million; the TTM figure through Mar 2026 stood at -$157.8 million (up 27.18% YoY), while the FY2025 annual figure was -$112.7 million, up 56.73% from the prior year.
- Enterprise Value for Q1 2026 stood at -$157.8 million, down from -$112.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$58.8 million in Q3 2025, with the low at -$449.9 million in Q1 2022.
- The 5-year median for Enterprise Value is -$216.7 million (2025), against an average of -$219.7 million.
- Peak annual rise in Enterprise Value reached 79.98% in 2022, while the deepest fall reached 583.81% in 2022.
- Tango Therapeutics' Enterprise Value stood at -$60.5 million in 2022, then declined by 11.08% to -$67.2 million in 2023, then tumbled by 287.39% to -$260.5 million in 2024, then jumped by 56.73% to -$112.7 million in 2025, then sank by 40.03% to -$157.8 million in 2026.
- Business Quant data shows TNGX's Enterprise Value at -$157.8 million in Q1 2026, -$112.7 million in Q4 2025, and -$58.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | -1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.01 Bn |
| Mar 31, 2026 | -157.83 Mn |
| Dec 31, 2025 | -112.71 Mn |
| Sep 30, 2025 | -58.77 Mn |
| Jun 30, 2025 | -180.79 Mn |
| Mar 31, 2025 | -216.72 Mn |
| Dec 31, 2024 | -260.48 Mn |
| Sep 30, 2024 | -293.28 Mn |
| Jun 30, 2024 | -322.11 Mn |
| Mar 31, 2024 | -343.60 Mn |
| Dec 31, 2023 | -67.24 Mn |
| Sep 30, 2023 | -359.88 Mn |
| Jun 30, 2023 | -310.65 Mn |
| Mar 31, 2023 | -333.64 Mn |
| Dec 31, 2022 | -60.54 Mn |
| Sep 30, 2022 | -100.88 Mn |
| Jun 30, 2022 | -105.15 Mn |
| Mar 31, 2022 | -449.89 Mn |
| Dec 31, 2021 | -145.59 Mn |
| Sep 30, 2021 | -503.81 Mn |